The International CoQ10 Association and Antioxidants journal has agreed to publish a special issue titled The Ubiquitous and Multifaceted Coenzyme Q, which will cover the new discoveries and research perspectives on CoQ and its role in health and diseases, and its importance in cellular redox homeostasis. A particular focus will be on studies on its biosynthesis and regulation. We invite all participants of the 10th International Scientific Meeting (Hamburg, May 12-15, 2022) to contribute to this special issue with original articles and reviews based on their recent results or expertise presented in the meeting.
Abstracts of 5 young student researchers will be chosen for the Young Participants Award. The name of the young authors must appear first in the author list and the abstract should be specified as a candidate for the award. Winners will have free registration and 5 mins to present their abstracts at the end of the specific session.
The following hotels have reduced rates for ICQA delegates from 11.05.2022 to 15.05.2022. When booking please specify the promotion code.
Dorint Hotel Hamburg-Eppendorf
Martinistrasse 72, 20251 Hamburg
134€/night single room
164€/night double room
30.03.22 remaining unreserved
rooms go on sale to the public
To apply please send a CV including a statement of research interests and names of 2 references to: Catarina M Quinzii (firstname.lastname@example.org), by February 29, 2020. Selected applicants will be invited to an interview in person or via Skype. Candidates will be informed about the selection by March 2020 with a projected June 2020 start date. The selected candidate must submit the necessary documents to Columbia University. Foreign applicants are encouraged to apply early to ensure adequate time to obtain visas
Alberto Sanz, PhD
Principal Research Associate
Institute for Cell and Molecular Biosciences &
Newcastle University Institute for Ageing
Campus for Ageing and Vitality
Newcastle upon Tyne
United Kingdome-mail: email@example.com
Tel: +44191 208 1221
Seville/Madrid, 2nd November 2016. The European Medicines Agency (EMA) has designated Ubiquinol as an orphan drug for the treatment of primary coenzyme Q10 deficiency, a serious rare disease which produces muscular, nervous system and kidney disorders and can cause failures of other organs.